Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea

Journal of Clinical Oncology

Volumn 28, Issue 18, 2010, Pages 2982-2988

  Dang, Chau ^a   Lin, Nancy ^a   Moy, Beverly ^a   Come, Steven ^a   Sugarman, Steven ^a   Morris, Patrick ^a   Abbruzzi, Alyson ^a   Chen, Carol ^a   Steingart, Richard ^a   Patil, Sujata ^a   Norton, Larry ^a   Winer, Eric ^a   Hudis, Clifford ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ACNE; ACNEIFORM; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER STAGING; CELLULITIS; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; SENSORY NEUROPATHY; SIDE EFFECT; SKIN PRURITUS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS HEPATITIS; VOMITING; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; ENZYME IMMUNOASSAY; FEASIBILITY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PILOT STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; FILGRASTIM; FOLLOW-UP STUDIES; GENE AMPLIFICATION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PILOT PROJECTS; QUINAZOLINES; RECEPTOR, ERBB-2; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77954586996     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.5900     Document Type: Article

References (32)

1. Dang C, Formier M, Sugarman S, et al: The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol 26:1216-1222, 2008
2. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
3. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005 (Pubitemid 46657378)
4. Geyer CE, Bryant JL, Romond EH, et al: Update of cardiac dysfunction on NSABP B-31: A randomized trial of sequential doxorubicin/cyclophosphamide and paclitaxel versus doxorubicin/cyclophosphamide and paclitaxel with trastuzumab. J Clin Oncol 24:23s, 2006 (suppl; abstract 581)
5. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
6. Piccart-Gebhart MJ, Procter M, Leyland- Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
7. Smith I, Proctor M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007 (Pubitemid 46039831)
8. Slamon DJ, Eiermann W, Robert NJ, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007
9. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006 (Pubitemid 43290919)
10. Spielman M, Roche H, Humblet T, et al: 3-year follow-up of trastuzumab following adjuvant chemotherapy with node-positive HER2-positive breast cancer patients: Results of the PACS 04 trial. Breast Cancer Res Treat 106:s19, 2007 (suppl 1; abstract 72)
11. Geyer CE, Forster J, Linquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
12. Storniolo AM, Pegram MD, Overmoyer B, et al: Phase II dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 26:3317-3323, 2008
13. Crown JP, Burris HA, Jones S, et al: Safety and tolerability of lapatinib in combination with taxanes in patients with breast cancer. J Clin Oncol 25:34s, 2007 (suppl; abstr 1027)
14. Henderson IC, Berry D, Demetri C, et al: Improved outcomes from the adding sequential paclitaxel but not from the escalation of doxorubicin in the adjuvant chemotherapy of patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003 (Pubitemid 46594124)
15. Mamounas EP, Bryant J, Lembersky BC, et al: Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP-B 28. J Clin Oncol 22:4a, 2003 (suppl; abstr 12)
16. Buzdar AU, Singletary SE, Valero V, et al: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial. Clin Cancer Res 8:1073-1079, 2002 (Pubitemid 34517642)
17. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003 (Pubitemid 46594092)
18. Tykerb (Lapatinib) Package Insert, June 1, 2007. Research Triangle Park, NC, GlaxoSmithKline, 2007
19. Rosner B. Fundamentals of Biostatistics (ed 3). Boston, MA, PWS-Kent Publishing, 1990, pp 82-83
20. Johnson BS, Dueck AC, Dakhil SR, et al: Tolerability of lapatinib given concurrently with paclitaxel and trastuzumab a spart of adjuvant therapy in patients with resected HER2+ breast cancer: Initial safety data from the Mayo Clinic Cancer Res Consortium trial RC0639. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008
21. Guarneri V, Frassoldati A, Bottini A, et al: Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. J Clin Oncol 27:24s, 2009 (suppl; abstr 573)
22. Crown JP, Burris HA, Boyle F, et al: Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 112:317-325, 2008
23. Seidman AD, Berry D, Cirrincione C, et al: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642-1649, 2008
24. Al-Dasooqi N, Bowen JM, Gibson RJ, et al: Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Invest New Drugs 27:173-178, 2009
25. Mason KA, Milas L, Peters LJ: Effect of paclitaxel alone and in combination with radiation on the gastrointestinal mucosa. Int J Radiat Oncol Biol Phys 32:1381-1389, 1995
26. Lapatinib Investigator's Brochure. Glaxo- SmithKline, Philadelphia, PA, GlaxoSmithKline, 2008
27. Ray M, Salgia R, Vokes EE: The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist 14:1116-1130, 2009
28. Stinchcombe TE, Socinski MA: Gefitinib in advanced non-small cell lung cancer: Does it deserve a second chance? Oncologist 13:933-944, 2008
29. Bose P, Ozer H: Neratinib: An oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs 18:1735-1751, 2009
30. Benson AB III, Ajani JA, Catalano RB, et al: Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22:2918-2926, 2004 (Pubitemid 41079912)
31. Perez EA, Koehler M, Byrne J, et al: Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 83:679-686, 2008 (Pubitemid 351810568)
32. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2- positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010